Exelixis, Inc.
EXEL
株式のランク
#1383
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer,... Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
株価
$64.01
最終同期: 2026-10-20
時価総額
$16.09B
変化（1日）
2.11%
変化（1年）
77.15%
国
US
取引 Exelixis, Inc. (EXEL)
カテゴリー
Healthcare
Exelixis, Inc.（EXEL）の収益
Jul 2026 時点の収益 TTM: $2.44B
Exelixis, Inc. の最新の財務報告によると、現在の収益 (TTM) は $2.44B です。2025 年には $2.17B の収益があり、これは 2023 年の $1.83B と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Exelixis, Inc. の収益履歴（2000 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $2.44B | 12.32% |
| 2025 | $2.17B | 18.49% |
| 2023 | $1.83B | 13.60% |
| 2022 | $1.61B | 12.27% |
| 2021 | $1.43B | 45.31% |
| 2020 | $987.54M | 2.04% |
| 2019 | $967.78M | 13.35% |
| 2018 | $853.83M | 88.70% |
| 2017 | $452.48M | 136.34% |
| 2016 | $191.45M | 415.05% |
| 2015 | $37.17M | 48.03% |
| 2014 | $25.11M | -19.87% |
| 2013 | $31.34M | -33.96% |
| 2012 | $47.45M | -83.62% |
| 2011 | $289.64M | 56.52% |
| 2010 | $185.05M | 21.93% |
| 2009 | $151.76M | 28.76% |
| 2008 | $117.86M | 3.87% |
| 2007 | $113.47M | 15.00% |
| 2006 | $98.67M | 29.90% |
| 2005 | $75.96M | 43.71% |
| 2004 | $52.86M | 2.56% |
| 2003 | $51.54M | 16.29% |
| 2002 | $44.32M | 8.09% |
| 2001 | $41.01M | 65.62% |
| 2000 | $24.76M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 418.26% |
US
|
|
| $2.23B | -8.54% |
US
|
|
| $15.74B | 546.34% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 147.19% |
NL
|
